LAUSR

Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial

Sign Up to like & get
recommendations!
0 Published in 2019 at "Journal of Thoracic Oncology"

DOI: 10.1016/j.jtho.2019.01.006

Abstract: Introduction: Data on immuno‐oncology agents in Chinese patients are limited despite a need for new therapies. We evaluated the efficacy and safety of nivolumab in a predominantly Chinese patient population with previously treated NSCLC. Methods:… read more here.

Keywords: versus docetaxel; population previously; previously treated; predominantly chinese ... See more keywords